Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways

• Published in: Journal of medicinal chemistry Vol. 62; no. 16; pp. 7383 - 7399
• Main Authors: Toselli, Francesca, Fredenwall, Marlene, Svensson, Peder, Li, Xue-Qing, Johansson, Anders, Weidolf, Lars, Hayes, Martin A
• Format: Journal Article
• Language: English
• Published: WASHINGTON American Chemical Society 22.08.2019; Amer Chemical Soc
• Subjects: Chemistry, Medicinal; Life Sciences & Biomedicine; Pharmacology & Pharmacy; Science & Technology; CYTOCHROME-P450; POTENT; PHARMACOKINETICS; CRYSTAL-STRUCTURE; ALDEHYDE OXIDASE; MICROSOMAL EPOXIDE HYDROLASE; CANDIDATE; INHIBITOR; DISCOVERY; STRATEGIES
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.9b00030

Oxetane-containing ring systems are increasingly used in medicinal chemistry programs to modulate druglike properties. We have shown previously that oxetanes are hydrolyzed to diols by human microsomal epoxide hydrolase (mEH). Mapping the enzymes that contribute to drug metabolism is important since an exaggerated dependence on one specific isoenzyme increases the risk of drug–drug interactions with co-administered drugs. Herein, we illustrate that mEH-catalyzed hydrolysis is an important metabolic pathway for a set of more structurally diverse oxetanes and the degree of hydrolysis is modulated by minor structural modifications. A homology model based on the Bombyx mori EH crystal structure was used to rationalize substrate binding. This study shows that oxetanes can be used as drug design elements for directing metabolic clearance via mEH, thus potentially decreasing the dependence on cytochromes P450. Metabolism by mEH should be assessed early in the design process to understand the complete metabolic fate of oxetane-containing compounds, and further study is required to allow accurate pharmacokinetic predictions of its substrates.